Clinical trial · Interventional
Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer
Efficacy of TTS Fentanyl in the Management of Pain in Patients With Malignancy - Study III
NCT00269737CI-TRIAL-00004884completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and effectiveness of continuous use of TTS fentanyl (a transdermal patch delivering the narcotic pain reliever fentanyl) for the treatment of chronic cancer pain.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fentanyl Transdermal Therapeutic System (TTS) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Pain intensity at designated time intervals
Secondary outcomes (1)
- measure
- Pharmacokinetics; Incidence of adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of intermediate stage of malignancy, operationally defined as non-localized or metastatic disease causing moderate to severe pain * Having a diagnosis of terminal disease, defined as life expectancy of six months or less, with moderate to severe pain associated with malignancy * Requiring treatment with a narcotic analgesic for relief of cancer pain * Having normal liver, kidney, and lung function, as determined by liver function tests, BUN, creatinine, and blood gases Exclusion Criteria: * Patients with a history of allergic reaction to narcotics * Having a history of narcotic abuse prior to cancer diagnosis * Unable to communicate adequately to provide information assessing the effectiveness of treatment * Having active skin disease which precludes application of the transdermal system * Having a history of carbon dioxide (CO2) retention or respiratory problems and who, in the physician's judgment, should not use narcotics
References
Publications (0)
Data not yet available
No reference posted for this study.